Clinical trials play an important part in helping to find out if new medicines are safe and effective. Yet a lack of awareness and feelings of hesitancy about joining one persist. Hear from a former clinical trial participant and a doctor who share why they think it’s important for others to consider participation.
MSD’s Post
More Relevant Posts
-
Clinical trials play an important part in helping to find out if new medicines are safe and effective. Yet a lack of awareness and feelings of hesitancy about joining one persist. Hear from a former clinical trial participant and a doctor who share why they think it’s important for others to consider participation.
A candid conversation about diversity in clinical trials
To view or add a comment, sign in
-
Participants are the MOST important aspect of any #clinicaltrial. Having a large, diverse group is important, but many companies struggle to find participants. If you have ever considered becoming a participant and have questions, check out this conversation with our friends at Merck:
Clinical trials play an important part in helping to find out if new medicines are safe and effective. Yet a lack of awareness and feelings of hesitancy about joining one persist. Hear from a former clinical trial participant and a doctor who share why they think it’s important for others to consider participation.
A candid conversation about diversity in clinical trials
To view or add a comment, sign in
-
Do you have a patient with a serious or immediately life-threatening disease or condition? Expanded access, sometimes called compassionate use, is a potential pathway for a patient with a serious or immediately life-threatening disease or condition to try an investigational medical product for treatment outside of clinical trials when there are no comparable or satisfactory therapies available. Patients should meet the following criteria: ☑️ There is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the disease or condition. ☑️ Patient enrollment in a clinical trial is not possible. ☑️ Potential patient benefit justifies the potential risks of treatment. ☑️ Providing the investigational medical product will not interfere with investigational trials that could support a medical product’s development or marketing approval for the treatment indication. Learn more about expanded access resources for patients & health care professionals ➡️ https://lnkd.in/eCDqQUDD Check out this guidance document featuring questions and answers regarding expanded access ➡️ https://lnkd.in/gXmZ-Gpr
To view or add a comment, sign in
-
Do you have a patient with a serious or immediately life-threatening disease or condition? Expanded access, sometimes called compassionate use, is a potential pathway for a patient with a serious or immediately life-threatening disease or condition to try an investigational medical product for treatment outside of clinical trials when there are no comparable or satisfactory therapies available. Patients should meet the following criteria: ☑️ There is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the disease or condition. ☑️ Patient enrollment in a clinical trial is not possible. ☑️ Potential patient benefit justifies the potential risks of treatment. ☑️ Providing the investigational medical product will not interfere with investigational trials that could support a medical product’s development or marketing approval for the treatment indication. Learn more about expanded access resources for patients & health care professionals ➡️ https://lnkd.in/eCDqQUDD Check out this guidance document featuring questions and answers regarding expanded access ➡️ https://lnkd.in/gXmZ-Gpr
To view or add a comment, sign in
-
Do you have a patient with a serious or immediately life-threatening disease or condition? Expanded access, sometimes called compassionate use, is a potential pathway for a patient with a serious or immediately life-threatening disease or condition to try an investigational medical product for treatment outside of clinical trials when there are no comparable or satisfactory therapies available. Patients should meet the following criteria: ☑️ There is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the disease or condition. ☑️ Patient enrollment in a clinical trial is not possible. ☑️ Potential patient benefit justifies the potential risks of treatment. ☑️ Providing the investigational medical product will not interfere with investigational trials that could support a medical product’s development or marketing approval for the treatment indication. Learn more about expanded access resources for patients & health care professionals ➡️ https://lnkd.in/eCDqQUDD Check out this guidance document featuring questions and answers regarding expanded access ➡️ https://lnkd.in/gXmZ-Gpr
To view or add a comment, sign in
-
Patients are more likely to express interest in clinical trial participation - if they are asked about their specific condition vs. a generic clinical trial. Our marketplace has tens of millions of patients with known conditions. Let SubjectWell ask specific patients about your specific clinical trial. Learn more at https://lnkd.in/gtPmM-_v #clinicalresearch #patientrecruitment
To view or add a comment, sign in
-
Passionate Life Sciences Leader | Fast-Tracking Treatments for Patients | Making a Positive Difference ❤️ | HBA Ambassador Champion | WEN (Women Empowerment Network) India Co-Lead
Pivotal trials that stand on their own could help biopharma manufacturers communicate the clinical value of medicines to payers and implement market access restrictions that allow patient access and result in better commercial performance. Embeding a patient access mindset and demonstrating total value to payers are ways to earn patient access through clinical trials.
To view or add a comment, sign in
-
Developing life saving/altering therapies is hard enough. Finding the right qualified participants for a clinical trial shouldn’t be. Join us for this insightful discussion to learn how there is a better way!
A staggering 80% of clinical trials struggle to meet accrual timelines. REGISTER NOW to learn how the challenges facing clinical trial enrollment are being addressed with innovative solutions that quickly identify and activate the right patients for your clinical trials. https://lnkd.in/gRg3gwC4 #clinicaltrials
To view or add a comment, sign in
-
Pivotal trials that stand on their own could help biopharma manufacturers communicate the clinical value of medicines to payers and implement market access restrictions that allow patient access and result in better commercial performance. Embeding a patient access mindset and demonstrating total value to payers are ways to earn patient access through clinical trials.
Boosting Clinical Trials and Patient Access with Payer Insights
share.postbeyond.com
To view or add a comment, sign in
-
Pivotal trials that stand on their own could help biopharma manufacturers communicate the clinical value of medicines to payers and implement market access restrictions that allow patient access and result in better commercial performance. Embeding a patient access mindset and demonstrating total value to payers are ways to earn patient access through clinical trials.
Boosting Clinical Trials and Patient Access with Payer Insights
share.postbeyond.com
To view or add a comment, sign in
1,042,543 followers